BLD-2660 / Blade Therap - LARVOL DELTA

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Blade Therapeutics | Active, not recruiting ➔ Completed | Trial completion date: Nov 2021 ➔ Jun 2021

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Small-molecule antiviral agents in ongoing clinical trials for COVID-19. (PubMed, Curr Drug Targets) - "These include viral polymerase and protease inhibitors remdesivir, galidesivir, favipiravir, ribavirin, sofosbuvir, tenofovir/emtricitabine, baloxavir marboxil, EIDD-2801, lopinavir/ritonavir; virus-/host-directed viral entry and fusion inhibitors arbidol chloroquine/hydroxychloroquine, chlorpromazine, camostat mesylate, nafamostat mesylate, bromhexine and agents with diverse/unclear mechanism of actions as oseltamivir, triazavirin, ivermectin, nitazoxanide, niclosamide and BLD-2660. The published preclinical and clinical data to date on these drugs as well as the mechanisms of action are reviewed."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF (clinicaltrials.gov) - P2a; N=0; Withdrawn; Sponsor: Blade Therapeutics; N=32 ➔ 0; Trial completion date: May 2021 ➔ Nov 2020; Suspended ➔ Withdrawn; Trial primary completion date: Mar 2021 ➔ Sep 2020

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases • EZR • S100A9 • Spectrin

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - P2; N=120; Active, not recruiting; Sponsor: Blade Therapeutics; Trial completion date: Nov 2020 ➔ Nov 2021

Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Healthy Volunteer Study Comparing Tablet and Capsule Formulations (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Blade Therapeutics; N=34 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Fibrosis • Immunology

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - P2; N=120; Active, not recruiting; Sponsor: Blade Therapeutics; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia (Businesswire) - "Blade Therapeutics today announced that it has reached the 120-subject enrollment goal for the Phase 2 clinical study of the Company’s investigational therapeutic, BLD-2660....Independent Data Monitoring Committee (DMC) recommended continuation of the trial without changes after conducting a planned review of blinded safety data....'We look forward to topline results in 4Q-2020.'"

DSMB • Enrollment closed • P2 data • Infectious Disease • Novel Coronavirus Disease

Healthy Volunteer Study Comparing Tablet and Capsule Formulations (clinicaltrials.gov) - P1; N=34; Not yet recruiting; Sponsor: Blade Therapeutics; Trial completion date: Nov 2019 ➔ Jul 2021; Trial primary completion date: Oct 2019 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date • Fibrosis • Immunology

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF (clinicaltrials.gov) - P2a; N=32; Suspended; Sponsor: Blade Therapeutics; Trial completion date: Dec 2020 ➔ May 2021; Initiation date: Apr 2020 ➔ Nov 2020; Not yet recruiting ➔ Suspended; Trial primary completion date: Aug 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Trial suspension • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases • EZR • S100A9 • Spectrin

Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia (Businesswire) - "Blade Therapeutics today announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients....The trial permits concomitant use of approved therapeutics including Remdesivir....'The timeline remains on track. We expect to complete enrollment in 3Q-2020 and provide topline results in 4Q-2020.'"

Enrollment status • P2 data • Infectious Disease • Novel Coronavirus Disease

Sorocabanos will test new medication in the treatment of Covid-19 [Google translation] (Jornal Cruzeiro do Sul) - "Sorocaba coronavirus patients will volunteer in a clinical research study to test the efficacy or otherwise of leading-edge drugs in the treatment of Covid-19. The unprecedented scientific work is being carried out in at least 40 hospitals worldwide....Of the five drugs that patients will receive, three already exist....They are: Ruxolitinib, Acalabrutinib and Lenzilumab (Humanigen). Two other drugs do not yet exist on the market and are called ANG-3777 (Angion) and BLD-2660 (Blade)."

Trial status • Infectious Disease • Novel Coronavirus Disease

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Blade Therapeutics; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects (clinicaltrials.gov) - P2; N=120; Not yet recruiting; Sponsor: Blade Therapeutics

Clinical • New P2 trial

First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis (clinicaltrials.gov) - P1a/1b; N=88; Completed; Sponsor: Blade Therapeutics; Recruiting ➔ Completed

Clinical • Trial completion

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF (clinicaltrials.gov) - P2a; N=32; Not yet recruiting; Sponsor: Blade Therapeutics

New P2a trial • EZR • Spectrin

Blade Therapeutics to present at the 31st Annual Piper Jaffray Healthcare Conference (Yahoo Finance) - "BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020."

New P2 trial • Trial completion